title: Cortical activation during cholinesterase-inhibitor treatment in Alzheimer disease: preliminary findings from a pharmaco-fMRI study.
abstract: OBJECTIVE
  Cholinesterase inhibitors improve cognitive functioning in Alzheimer disease (AD). The authors studied, with functional magnetic resonance imaging (fMRI), the neural mechanism by which this cholinergic enhancement improves memory encoding in AD over longer time periods.
  
  
  METHODS
  Brain activation was measured in 10 patients with AD and 10 healthy elderly comparison subjects with fMRI while they were encoding novel faces. Patients were scanned again after a 10-week open treatment with the cholinesterase-inhibitor donepezil.
  
  
  RESULTS
  Neuropsychologically-tested memory performance improved during the treatment phase in the patients. During the encoding of novel faces, elderly comparison subjects showed more activation in the right fusiform gyrus than the group of AD patients. After a 10-week treatment with donepezil, the fusiform gyrus was also activated in patients, similar to the comparison group.
  
  
  CONCLUSIONS
  The right fusiform gyrus is associated with the processing of faces. Cholinergic enhancement augments selective attention by increased selectivity of perceptual responses in patients with AD. This mechanism may contribute to a more efficient processing of the attended stimulus and thus be a mechanism underlying clinical improvement of cognitive functioning. These promising preliminary findings need to be confirmed in a larger, controlled trial in which both fMRI and attention measures serve as outcomes.
authors.affiliation: Dept. of Psychiatry, Univ. of Tübingen, Tübingen, Germany. tkircher@ukaachen.de
authors.forename: Tilo T J
authors.initials: TT
authors.lastname: Kircher
authors.forename: Michael
authors.initials: M
authors.lastname: Erb
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Grodd
authors.forename: Dirk T
authors.initials: DT
authors.lastname: Leube
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology; D001931:Brain Mapping; D002540:Cerebral Cortex / Q000187:drug effects* / Q000503:physiopathology; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000188:drug therapy / Q000503:physiopathology; D004292:Dominance, Cerebral / Q000187:drug effects / Q000502:physiology; D000077265:Donepezil; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005145:Face; D005260:Female; D006801:Humans; D007189:Indans / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D008570:Memory, Short-Term / Q000187:drug effects / Q000502:physiology; D008875:Middle Aged; D010364:Pattern Recognition, Visual / Q000187:drug effects / Q000502:physiology; D010880:Piperidines / Q000627:therapeutic use*; D020238:Prosopagnosia / Q000188:drug therapy* / Q000503:physiopathology; D011597:Psychomotor Performance / Q000187:drug effects / Q000502:physiology
chemical_list: D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D000077265:Donepezil